A 48-year-old woman with a 10-year history of type 2 diabetes mellitus presents with a 3-day history of severe diarrhea and vomiting following food poisoning. She has not eaten for 2 days. On examination, she appears dehydrated (mucous membranes dry, skin turgor reduced). Laboratory findings: blood glucose 65 mg/dL, serum insulin 18 mIU/L, plasma glucagon 450 pg/mL (normal fasting: 50–100 pg/mL), serum ketones negative, arterial pH 7.38, HCO₃⁻ 24 mEq/L. She is on metformin and a sulfonylurea (gliclazide). What is the most likely explanation for the hypoglycemia despite elevated glucagon levels?

Explanation

## Sulfonylurea-Induced Hypoglycemia with Inadequate Glucagon Response ### Clinical Context A patient on a sulfonylurea (gliclazide) presenting with hypoglycemia (65 mg/dL) despite elevated glucagon (450 pg/mL) in the setting of prolonged fasting and dehydration. The key insight is that glucagon IS elevated and IS responding appropriately—but it is **insufficient** to overcome the hypoglycemic effect of the sulfonylurea. ### Why Glucagon Is Elevated but Ineffective **Key Point:** Sulfonylureas cause insulin secretion **independent of blood glucose levels**. They block K-ATP channels in beta cells, forcing continuous insulin release regardless of the metabolic state. 1. **Sulfonylurea mechanism:** - Gliclazide blocks ATP-sensitive K⁺ channels → beta-cell depolarization - Continuous Ca²⁺ influx → unregulated insulin secretion - Insulin is secreted even when blood glucose is low (pathological) 2. **Why glucagon cannot fully compensate:** - Glucagon IS elevated (450 pg/mL) and IS attempting to mobilize glucose - However, the patient has been fasting for 2 days → **hepatic glycogen stores are severely depleted** - Glucagon can only stimulate glycogenolysis if glycogen is available - Gluconeogenesis is activated but cannot generate glucose fast enough to overcome the ongoing insulin-mediated glucose uptake and suppression of hepatic glucose output - The net effect: insulin action > glucagon action → hypoglycemia persists ### Hepatic Glycogen Depletion Timeline ```mermaid flowchart TD A[Prolonged fasting 2 days]:::outcome --> B[Hepatic glycogen stores depleted]:::outcome C[Sulfonylurea administration]:::action --> D[Continuous insulin secretion]:::outcome D --> E[Glucose uptake by muscle/adipose ↑↑]:::action B --> F[Glycogenolysis capacity ↓↓]:::outcome F --> G[Glucagon response inadequate]:::outcome E --> H[Hypoglycemia 65 mg/dL]:::urgent G --> H H --> I[Elevated glucagon cannot overcome insulin excess]:::outcome ``` ### Why Serum Ketones Are Negative **High-Yield:** Despite fasting, serum ketones are **negative** because: - Insulin (though inappropriately elevated) still suppresses lipolysis - Insulin inhibits hormone-sensitive lipase in adipose tissue - Without free fatty acid mobilization, ketone body synthesis is minimal - This distinguishes sulfonylurea-induced hypoglycemia from hypoglycemia due to true insulin deficiency (e.g., type 1 DM with fasting) ### Comparison: Glucagon Response in Different Scenarios | Scenario | Glucagon Level | Hypoglycemia Mechanism | Ketones | |----------|----------------|------------------------|----------| | **Sulfonylurea + fasting (this case)** | **↑↑ (450)** | Depleted glycogen + continuous insulin | Negative | | Type 1 DM with fasting | ↑↑↑ | Absent insulin, no glycogen | Positive | | Liver failure | Normal/↑ | Loss of gluconeogenesis capacity | Variable | | Alpha-cell autoimmunity | Low/absent | No glucagon response | Positive | **Clinical Pearl:** The presence of **elevated glucagon with negative ketones and hypoglycemia** is virtually pathognomonic for **sulfonylurea-induced hypoglycemia in a fasting state**. The glucagon is doing its job, but the substrate (glycogen) and the metabolic environment (insulin suppression of lipolysis) prevent adequate glucose recovery. ### Management Implications **Tip:** In this patient: 1. Immediate IV dextrose to raise blood glucose 2. **Discontinue sulfonylurea** (gliclazide) immediately 3. Switch to insulin-independent agents (e.g., metformin alone, DPP-4 inhibitors, SGLT-2 inhibitors) 4. Educate on avoiding prolonged fasting while on sulfonylureas [cite:KD Tripathi 8e Ch 25; Harrison 21e Ch 417]